← Leaderboards
Peter Hugh O'Donnell
University Of Chicago
$8,826,322
Attributed
$11,365,892
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,365,892 · 6
By mechanism
R01$6,629,849 · 2
T32$3,264,798 · 1
K23$750,760 · 1
R21$687,963 · 1
F32$32,522 · 1
Top collaborators
- Mark J Ratain6 shared
- M Eileen Dolan5 shared
- Sean P. David2 shared
- David O Meltzer2 shared
Most similar at University Of Chicago
Same institution · by research overlap
- Nancy J. Cox$31,978,299
- Maryellen L. Giger$19,209,750
- Olufunmilayo I Olopade$31,360,913
- James P. Zacny$6,008,136
- M Eileen Dolan$15,055,139
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsToxic EffectPharmacogenomicsDoseHigh RiskResponseMedicalVariantProspectiveGenesPublic HealthPerceptionTechnologyAdoptionGeneticRandomizedAdoptedGenomicsDecision MakingPreventGenetic VariantAdverse EventResourcesGenotype
Grant awards (21)
Pharmacogenomics to Catalyze Decision Support in Oncology Care$867,396
R01 · FY2025 · HG · contact PI
Clinical Therapeutics$573,622
T32 · FY2025 · GM · contact PI
Integrative Analyses of Clinical Pharmacogenetic Data to Prevent Hospital Readmission in Real-World Health Systems$334,235
R21 · FY2025 · HG
Pharmacogenomics to Catalyze Decision Support in Oncology Care$867,862
R01 · FY2024 · HG · contact PI
Integrative Analyses of Clinical Pharmacogenetic Data to Prevent Hospital Readmission in Real-World Health Systems$353,728
R21 · FY2024 · HG
Clinical Therapeutics$301,147
T32 · FY2024 · GM · contact PI
Pharmacogenomics to Catalyze Decision Support in Oncology Care$884,216
R01 · FY2023 · HG · contact PI
Clinical Therapeutics$632,158
T32 · FY2023 · GM · contact PI
Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care - Resubmission 01$809,925
R01 · FY2022 · HG · contact PI
Clinical Therapeutics$615,118
T32 · FY2022 · GM
Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care - Resubmission 01$809,537
R01 · FY2021 · HG · contact PI
Clinical Therapeutics$586,974
T32 · FY2021 · GM
Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care - Resubmission 01$809,934
R01 · FY2020 · HG · contact PI
Clinical Therapeutics$555,779
T32 · FY2020 · GM
Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care - Resubmission 01$809,934
R01 · FY2019 · HG · contact PI
Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care - Resubmission 01$771,045
R01 · FY2018 · HG · contact PI
The 1200 Patients Project: Studying Clinical Implementation of Pharmacogenomics$185,693
K23 · FY2016 · GM · contact PI
The 1200 Patients Project: Studying Clinical Implementation of Pharmacogenomics$187,126
K23 · FY2015 · GM · contact PI
The 1200 Patients Project: Studying Clinical Implementation of Pharmacogenomics$188,293
K23 · FY2014 · GM · contact PI
The 1200 Patients Project: Studying Clinical Implementation of Pharmacogenomics$189,648
K23 · FY2013 · GM · contact PI
Population-Specific Genetic Determinants of Susceptibility to Chemotherapies$32,522
F32 · FY2009 · CA · contact PI